PAVmed Inc. – NASDAQ:PAVM
PAVmed stock price today
$0.421
-0.22
-35.11%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
PAVmed stock price monthly change
-24.56%
month
PAVmed stock price quarterly change
-24.56%
quarter
PAVmed stock price yearly change
-84.19%
year
PAVmed key metrics
Market Cap | 7.62M |
Enterprise value | 31.64M |
P/E | -0.39 |
EV/Sales | 83.92 |
EV/EBITDA | -0.37 |
Price/Sales | 92.17 |
Price/Book | -3.58 |
PEG ratio | N/A |
EPS | -7.93 |
Revenue | 3.01M |
EBITDA | -60.55M |
Income | -61.53M |
Revenue Q/Q | 126.45% |
Revenue Y/Y | 375.70% |
Profit margin | -23602.92% |
Oper. margin | -24072.68% |
Gross margin | -858.36% |
EBIT margin | -24072.68% |
EBITDA margin | -2007.63% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePAVmed stock price history
PAVmed stock forecast
PAVmed financial statements
| Jun 2023 | 166K | -14.53M | -8757.23% |
|---|---|---|---|
| Sep 2023 | 791K | -17.74M | -2243.74% |
| Dec 2023 | 1.04M | -14.03M | -1338.04% |
| Mar 2024 | 1.01M | -15.21M | -1506.14% |
| Mar 2024 | 1.01M | -15.21M | -1506.14% |
|---|---|---|---|
| Sep 2025 | 2.3M | 0 | |
| Oct 2025 | 2.3M | 0 | |
| Dec 2025 | 4.8M | 0 |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 53683000 | 54.51M | 101.55% |
|---|---|---|---|
| Sep 2023 | 42020000 | 57.84M | 137.67% |
| Dec 2023 | 33119000 | 57.13M | 172.52% |
| Mar 2024 | 37254000 | 57.82M | 155.23% |
| Jun 2023 | -12.78M | -15K | 684K |
|---|---|---|---|
| Sep 2023 | -11.08M | -18K | 352K |
| Dec 2023 | -11.87M | -183K | 5.28M |
| Mar 2024 | -13.10M | -42K | 19.04M |
PAVmed alternative data
| Aug 2023 | 124 |
|---|---|
| Sep 2023 | 124 |
| Oct 2023 | 124 |
| Nov 2023 | 124 |
| Dec 2023 | 124 |
| Jan 2024 | 124 |
| Feb 2024 | 124 |
| Mar 2024 | 124 |
| Apr 2024 | 124 |
| May 2024 | 107 |
| Jun 2024 | 107 |
| Jul 2024 | 107 |
PAVmed other data
94.88%
+1.40%
of PAVM is owned by hedge funds
60
-10
12.30M
+181.78K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 250000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | GLENNON MICHAEL J director | Common Stock | 100,000 | $0.62 | $62,300 | ||
Purchase | GLENNON MICHAEL J director | Common Stock | 88,000 | $0.64 | $56,056 | ||
Purchase | GLENNON MICHAEL J director | Common stock | 62,000 | $0.69 | $42,594 | ||
Purchase | AKLOG LISHAN director, 10 perc.. | Common Stock | 7,500 | N/A | N/A | ||
Purchase | AKLOG LISHAN director, 10 perc.. | Common Stock | 7,500 | N/A | N/A | ||
Sale | SIROVICH MATTHEW 10 percent owner | Common Stock | 33,203 | $1.96 | $65,045 | ||
Sale | SIROVICH MATTHEW 10 percent owner | Common Stock | 53,036 | $2 | $105,860 | ||
Sale | SIROVICH MATTHEW 10 percent owner | Common Stock | 75,211 | $1.83 | $137,410 | ||
Sale | SIROVICH MATTHEW 10 percent owner | Common Stock | 24,789 | $1.78 | $44,174 | ||
Sale | SIROVICH MATTHEW 10 percent owner | Common Stock | 131,082 | N/A | N/A |
| Patent |
|---|
Grant Filling date: 27 Apr 2018 Issue date: 1 Mar 2022 |
Application Filling date: 17 Aug 2021 Issue date: 24 Feb 2022 |
Application Filling date: 4 Oct 2021 Issue date: 27 Jan 2022 |
Application Filling date: 9 Jul 2021 Issue date: 6 Jan 2022 |
Application Filling date: 27 May 2020 Issue date: 2 Dec 2021 |
Grant Filling date: 27 Apr 2018 Issue date: 12 Oct 2021 |
Application Filling date: 15 May 2020 Issue date: 19 Nov 2020 |
Application Filling date: 10 Apr 2020 Issue date: 15 Oct 2020 |
Grant Filling date: 23 Jan 2019 Issue date: 23 Jun 2020 |
Grant Filling date: 27 Apr 2018 Issue date: 8 Oct 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 15 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 16 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Lishan Aklog M.D. (1966) Chairman & Chief Executive Officer | $686,300 |
Mr. Dennis M. McGrath CPA (1957) Pres, Chief Financial Officer & Corporation Sec. | $517,700 |
| Dr. Brian J. deGuzman M.D. (1965) Chief Medical Officer & Executive Vice President of Clinical Affairs | $427,200 |
-
What's the price of PAVmed stock today?
One share of PAVmed stock can currently be purchased for approximately $0.42.
-
When is PAVmed's next earnings date?
Unfortunately, PAVmed's (PAVM) next earnings date is currently unknown.
-
Does PAVmed pay dividends?
No, PAVmed does not pay dividends.
-
How much money does PAVmed make?
PAVmed has a market capitalization of 7.62M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 550.4% to 2.45M US dollars.
-
What is PAVmed's stock symbol?
PAVmed Inc. is traded on the NASDAQ under the ticker symbol "PAVM".
-
What is PAVmed's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of PAVmed?
Shares of PAVmed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are PAVmed's key executives?
PAVmed's management team includes the following people:
- Dr. Lishan Aklog M.D. Chairman & Chief Executive Officer(age: 59, pay: $686,300)
- Mr. Dennis M. McGrath CPA Pres, Chief Financial Officer & Corporation Sec.(age: 68, pay: $517,700)
- Dr. Brian J. deGuzman M.D. Chief Medical Officer & Executive Vice President of Clinical Affairs(age: 60, pay: $427,200)
-
How many employees does PAVmed have?
As Jul 2024, PAVmed employs 107 workers, which is 14% less then previous quarter.
-
When PAVmed went public?
PAVmed Inc. is publicly traded company for more then 9 years since IPO on 27 Jul 2016.
-
What is PAVmed's official website?
The official website for PAVmed is pavmed.com.
-
Where are PAVmed's headquarters?
PAVmed is headquartered at One Grand Central Place, New York, NY.
-
How can i contact PAVmed?
PAVmed's mailing address is One Grand Central Place, New York, NY and company can be reached via phone at +212 9494319.
PAVmed company profile:
PAVmed Inc.
pavmed.comExchange:
NASDAQ
Full time employees:
107
Industry:
Medical - Devices
Sector:
Healthcare
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
One Grand Central Place
New York, NY 10165
New York, NY 10165
CIK: 0001624326
ISIN: US70387R4039
CUSIP: 70387R106
